SPIA
VIRX

Steward Partners Investment Advisory’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Steward Partners Investment Advisory’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17
Closed -$157 – 7458
2021
Q1 		$157 Sell
17
-1
-6% -$10 ﹤0.01% 3379
2020
Q4 		$0 Buy
+18
New +$94 ﹤0.01% 3013
2020
Q3 		– Sell
-1
Closed – – 2876
2020
Q2 		$0 Hold
1
– – ﹤0.01% 2767
2020
Q1 		$0 Hold
1
– – ﹤0.01% 2734
2019
Q4 		$0 Hold
1
– – ﹤0.01% 2767
2019
Q3 		$0 Buy
+1
New +$29 ﹤0.01% 2791

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Steward Partners Investment Advisory's VIRX Position: Q2 2021 in Review

Steward Partners Investment Advisory sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2021, closing a stake of 17 shares — an estimated $157 sold.

Steward Partners Investment Advisory first reported a position in VIRX in Q3 2019 and held it in 6 quarters. The position peaked at $157 in Q1 2021. 63 funds tracked by Wall St. Rank hold VIRX as of Q2 2021.

  • Steward Partners Investment Advisory reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Steward Partners Investment Advisory sold 17 Viracta Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $157.
  • Steward Partners Investment Advisory first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2019 and held it in 6 quarters.
  • Steward Partners Investment Advisory's Viracta Therapeutics, Inc. Common Stock position peaked at $157 in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2021, filed 13 Aug 2021.